Vitamin D metabolites and/or analogs: Which D for which patient?

Current Vascular Pharmacology

Volumn 12, Issue 2, 2014, Pages 339-349

  Mazzaferro, S ^a   Goldsmith, D ^b   Larsson, T E ^c,d   Massy, Z A ^e   Cozzolino, M ^f  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c KAROLINSKA INSTITUTE   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e INSERM   (France)

^f UNIVERSITY OF MILAN   (Italy)

Author keywords

Alphacalcidol; Calcifediol; Calcitriol; Cholecalciferol; Doxercalciferol; Ergocalciferol; Oxacalcitriol; Paricalcitol

Indexed keywords

ALFACALCIDOL; CALCIFEDIOL; CALCITRIOL; CALCIUM; COLECALCIFEROL; DOXERCALCIFEROL; ERGOCALCIFEROL; FIBROBLAST GROWTH FACTOR; OXACALCITRIOL; PARATHYROID HORMONE; PARICALCITOL; PHOSPHATE; UNCLASSIFIED DRUG; VITAMIN D;

ARTICLE; CHRONIC KIDNEY DISEASE; ENZYME ACTIVITY; EVIDENCE BASED PRACTICE; HEART FUNCTION; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; HYPERPHOSPHATEMIA; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY FUNCTION; PROTEINURIA; REGULATORY MECHANISM; RENAL REPLACEMENT THERAPY; RISK FACTOR; SURVIVAL RATE;

EID: 84920460544     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/15701611113119990024     Document Type: Article

References (99)

1. [1] Armas LA, Hollis BW, Heaney RP. Vitamin D2 is much less effec-tive than vitamin D3 in humans. J Clin Endocrinol Metab 2004; 89(11): 5387-5391.
2. [2] Houghton LA, Vieth R. The case against ergocalciferol (vitaminD2) as a vitamin supplement. Am J Clin Nutr 2006; 84: 694-7.
3. [3] Nigwekar SU, Bhan I, Thadhani R. Ergocalciferol and Cholecalcif-erol in CKD. Am J Kidney Dis 2012; 60(1): 139-156.
4. [4] Institute of Medicine. Dietary Reference Intakes for Calcium and Vitamin D. Washington, D.C.: National Academies Press, 2010.
5. [5] Dawson-Hughes B, Mithal A, Bonjour JP, et al. IOF position statement: vitamin D recommendations for older adults.Osteoporos Int 2010; 21: 1151-4.
6. [6] Ngo DT, Stafford I, Kelly DJ, et al. Vitamin D(2) supplementation induces the development of aortic stenosis in rabbits: interactions with endothelial function and thioredoxin-interacting protein. Eur J Pharmacol 2008; 590(1-3): 290-6.
7. [7] Hsia J, Heiss G, Ren H, et al. Calcium/vitamin D supplementation and cardiovascular events. Circulation 2007; 115: 846-854.
8. [8] Vacek JL, Vanga SR, Good M, Lai SM, Lakkireddy D, Howard PA. Vitamin D deficiency and supplementation and relation to car- diovascular health. Am J Cardiol 2012; 109(3): 359-63.
9. [9] National Kidney Founation. K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am J Kidney Dis 2003; 42(4): S1-S201.
10. [10] Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO Clinical Practice Guideline for the Di- agnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009; 113: S1-130.
11. [11] Kandula P, Dobre M, Schold JD, Schreiber MJ, Mehrotra R, Nava-neethan SD. Vitamin D supplementation in chronic kidney disease: a systematic review and meta-Analysis of observational studies and randomized controlled trials. Clin J Am Soc Nephrol 2011; 6: 50-62.
12. [12] Kim MJ, Frankel AH, Donaldson M, et al. Oral cholecalciferol decreases albuminuria and urinary TGF- 1 in patients with type 2 diabetic nephropathy on established renin-angiotensin-aldosterone system inhibition. Kidney Int 2011; 80(8): 851-60.
13. [13] Rossini M, Gatti D, Viapiana O, et al. Short-term effects on bone turnover markers of a single high dose of oral vitamin D. Short- term effects on bone turnover markers of a single high dose of oral vitamin D.J Clin Endocrinol Metab 2012; 97(4): E622-6.
14. [14] Brandenburg V, Kruger T. Calcifediol - more than the stepchild of CKD-MBD therapy? Curr Vasc Pharmacol 2013; 12(2): 286-293.
15. [15] Bischoff-Ferrari HA, Dawson-Hughes B, Stocklin E, et al. Oral supplementation with 25(OH)D(3) versus vitamin D(3): effects on 25(OH)D levels, lower extremity function, blood pressure and markers of innate immunity. J Bone Miner Res 2012; 27(1): 160-169.
16. [16] Cashman KD, Seamans KM, Lucey AJ, et al. Relative effectiveness of oral 25-hydroxyvitamin D3 and vitamin D3 in raising win- tertime serum 25-hydroxyvitamin D in older adults. Am J Clin Nutr 2012; 95(6): 1350-1356.
17. [17] Michaud J, Naud J, Ouimet D, et al. Reduced hepatic synthesis of calcidiol in uremia. J Am Soc Nephrol 2010; 21(9): 1488-1497.
18. [18] Jean G, Terrat JC, Vanel T, et al. Daily oral 25-hydroxycholecal ciferol supplementation for vitamin D deficiency in haemodialysis patients: effects on mineral metabolism and bone markers. Nephrol Dial Transplant 2008; 23(11): 3670-3676.
19. [19] Lomonte C, Casucci F, Libutti P, Losurdo N, Teutonico A, Basile C. Vitamin D treatment in hemodialysis patients with low serum levels of parathyroid hormone: which is the best choice? J Nephrol 2010; 23(2): 210-215.
20. [20] Kanter BJ, Crespo AJ, Beltran CS, et al. Vitamin D deficiency in a renal transplant population: safe repletion with moderate doses of calcidiol. Transplant Proc 2010; 42(8): 2917-2920.
21. [21] Buccianti G, Bianchi ML, Valenti G, Lorenz M, Cresseri D. Effects of calcifediol treatment on the progression of renal osteodystrophy during continuous ambulatory peritoneal dialysis. Nephron 1990; 56(4): 353-356.
22. [22] Teitelbaum SL, Bone JM, Stein PM, et al. Calcifediol in chronic renal insufficiency. Skeletal response. JAMA 1976; 235(2): 164-167.
23. [23] Zucchelli P, Catizone L, Casanova S, Fabbri L, Fusaroli M. Therapeutic effects of 25-hydroxycholecalciferol and sodium etidronate on renal osteodystrophy. Miner Electrolyte Metab 1982; 7(2): 86-96.
24. [24] Coen G, Taccone GM, Bonucci E, et al. 1,25(OH)2D3 and 25-OHD3 in the treatment of renal osteodystrophy: comparison of combined versus 1,25(OH)2D3 administration alone. Min Electro- lyte Metab 1983; 9: 19-27.
25. [25] Rodriguez M, Muñoz J, Almaden Y. Therapeutic uses of Calcitriol. Curr Vasc Pharamacol 2013; 12(2): 294-299.
26. [26] Schwarz U, Amann K, Orth SR, et al. Effect of 1,25 (OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rats. Kid- ney Int 1998; 53: 1696-1705.
27. [27] Kuhlmann A, Haas CS, Gross ML, et al. 1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subto- tally nephrectomized rat. Am J Physiol Renal Physiol 2004; 286(3): F526-33.
28. [28] Migliori M, Giovannini L, Panichi V, et al. Treatment with 1,25-dihydroxyvitamin D3 preserves glomerular slit diaphragm- associated protein expression in experimental glomerulonephritis. Int J Immunopathol Pharmacol 2005; 18(4): 779-90.
29. [29] Cardús A, Panizo S, Parisi E, Fernandez E, Valdivielso JM. Differential effects of vitamin D analogs on vascular calcification. J Bone Miner Res 2007; 22(6): 860-6.
30. [30] Cardús A, Parisi E, Gallego C, Aldea M, Fernández E, Valdivielso JM. 1,25-Dihydroxyvitamin D3 stimulates vascular smooth muscle cell proliferation through a VEGF-mediated pathway. Kidney Int 2006; 69(8): 1377-84.
31. [31] Mathew S, Lund RJ, Chaudhary LR, Geurs T, Hruska KA. Vitamin D receptor activators can protect against vascular calcification. J Am Soc Nephrol 2008; 19(8): 1509-1519.
32. [32] Mizobuchi M, Finch JL, Martin DR, Slatopolsky E. Differential effects of vitamin D receptor activators on vascular calci cation in uremic rats. Kidney Int 2007; 72(6): 709-715.
33. [33] Becker LE, Koleganova N, Piecha G, et al. Effect of paricalcitol and calcitriol on aortic wall remodeling in uninephrectomized ApoE knockout mice. Am J Physiol Renal Physiol 2011; 300(3): F772-82.
34. [34] Haffner D, Hocher B, Müller D, et al. Systemic cardiovascular disease in uremic rats induced by 1,25(OH)2D3. J Hypertens 2005; 23(5): 1067-75.
35. [35] Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007; 71: 31-38.
36. [36] Inaguma D, Nagaya H, Hara K, et al. Relationship between serum 1,25- dihydroxyvitamin D and mortality in patients with pre- dialysis chronic kidney disease. Clin Exp Nephrol 2008; 12: 126-131.
37. [37] Slatopolsky E, Weerts C, Thielan J, et al. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxycholecalciferol in uremic patients. J Clin Invest 1984; 74(6): 2136-2143.
38. [38] Andress DL, Keith MD, Norris C, et al. Intravenous calcitriol in the treatment of refractory osteitis brosa of chronic renal failure. N Engl J Med 1989; 321: 274-279.
39. [39] Szeto CC, Chow KM, Kwan BC, et al. Oral calcitriol for the treat-ment of persistent proteinuria in immunoglobulin A nephropathy: an uncontrolled trial. Am J Kidney Dis 2008; 51: 724-731.
40. [40] Holick MF, Semmler EJ, Schnoes HK, DeLuca HF. 1 –Hydroxy derivative of vitamin D 3: a highly potent analog of 1,25- dihydroxyvitamin D 3. Science 1973; 180(4082): 190-1.
41. [41] Chalmers TM, Hunter JO, Davie MW, Szaz KF, Pelc B, Kodicek E. 1-Alpha-hydroxycholecalciferol as a substitute for the kidney hormone 1,25-dihydroxycholecalciferol in chronic renal failure. Lancet 1973;2(7831):696-9.
42. [42] Vervloet M. Clinical uses of 1-alpha-hydroxycholecalciferol. Curr Vasc Pharmacol 2013; 12(2): 300-5.
43. [43] Shiraishi A, Takeda S, Masaki T, Higuchi Y, Uchiyama Y, Kubodera N, Sato K, Ikeda K, Nakamura T, Matsumoto T, Ogata E. Alfacalcidol inhibits bone resorption and stimulates formation in an ovariectomized rat model of osteoporosis: distinct actions from es- trogen. J Bone Miner Res 2000;15(4):770-9.
44. [44] Shiraishi A, Higashi S, Masaki T, Saito M, Ito M, Ikeda S, Nakamura T. A comparison of alfacalcidol and menatetrenone for the treatment of bone loss in an ovariectomized rat model of osteopo- rosis. Calcif Tissue Int 2002;71(1):69-79.
45. [45] Brown AJ, Ritter CS, Knutson JC et al. The vitamin D prodrugs 1alpha(OH)D2, 1alpha(OH)D3 and BCI-210 suppress PTH secre- tion by bovine parathyroidNephrol Dial Transplant 2006; 21(3):644-50.
46. [46] Krog M, Ejerblad S, Eriksson I, Johansson H. Arterial calcifications in uraemic rats treated with 1-alpha-hydroxycholecalciferol and parathyroidectomy. Scand J Urol Nephrol 1984;18(3):227-39.
47. [47] O'Donnell S, Moher D, Thomas K, Hanley DA, Cranney A. Systematic review of the benefits and harms of calcitriol and alfacalci- dol for fractures. J Bone Miner Metab 2008;26(6):531-42.
48. [48] Hamdy NA, Kanis JA, Beneton MN, et al. Effects of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. Br Med J 1995; 310:358-63.
49. [49] Hansen D, Rasmussen K, Danielsen H, et al. No difference between alfacalcidol and paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients: a randomized cross- over trial. Kidney Int 2011; 80(8):841-50.
50. [50] St-Arnaud R, Arabian A, Akhouayri O, Knutson JC, Strugnell SA. Differential Effects of Oral Doxercalciferol (Hectorol(R)) or Paricalcitol (Zemplar(R)) in the Cyp27b1-Null Mouse Model of Uremia. Nephron Exp Nephrol 2011; 119: e67-e74.
51. [51] Ritter CS, Brown AJ. Direct suppression of Pth gene expression by the vitamin D prohormones doxercalciferol and calcidiol requires the vitamin D receptor. J Mol Endocrinol 2011; 46: 63-6.
52. [52] Park J, Rhee C, Ling Lau W, Kalantar- Zadeh K. Clinical uses of 1-alpha-hydroxy-Ergocalciferol. Curr Vasc Pharmacol 2013; 12(2): 306-12.
53. [53] Zhang Y, Deb DK, Kong J, et al. Long-term therapeutic effect of vitamin D analog doxercalciferol on diabetic nephropathy: strong synergism with AT1 receptor antagonist. Am J Physiol Renal Physiol 2009; 297: F791-801.
54. [54] Tentori F, Hunt WC, Stidley CA, et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 2006; 70: 1858-65.
55. [55] Maung HM, Elangovan L, Frazao JM, et al. Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha- hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparison. Am J Kidney Dis 2001; 37: 532-43.
56. [56] Zisman AL, Ghantous W, Schinleber P, Roberts L, Sprague SM. Inhibition of parathyroid hormone: a dose equivalency study of paricalcitol and doxercalciferol. Am J Nephrol 2005; 25: 591-5.
57. [57] Fadem SZ, Al-Saghir F, Zollner G, Swan S. Converting hemodialysis patients from intravenous paricalcitol to intravenous doxercalciferol - a dose equivalency and titration study. Clin Nephrol 2008; 70: 319-24.
58. [58] Coburn JW, Maung HM, Elangovan L, et al. Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am J Kidney Dis 2004; 43: 877-90.
59. [59] Moe SM, Saifullah A, LaClair RE, Usman SA, Yu Z. A randomized trial of cholecalciferol versus doxercalciferol for lowering parathyroid hormone in chronic kidney disease. Clin J Am Soc Nephrol 2010; 5: 299-306.
60. [60] Dusso A. Kidney disease and vitamin D levels: 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and VDR activation. Kidney Int Suppl 2012; 1 (4): 136-141.
61. [61] Brown AJ, Finch J, Slatopolsky E. Differential effects of 19-nor1,25-dihydroxyvitamin D(2) and 1,25-dihydroxyvitamin D(3) on intestinal calcium and phosphate transport. J Lab Clin Med 2002; 139: 279-84.
62. [62] Noertersheuser PA, Pradhan RS, Klein CE, et al. Exposure-clinical response analysis of paricalcitol in patients with chronic kidney disease (stage 5) on hemodialysis or peritoneal dialysis. J Clin Pharmacol 2012; 52: 1162-73.
63. [63] Coyne D, Acharya M, Qiu P, et al. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis 2006; 47: 263-76.
64. [64] Martin KJ, Gonzalez EA, Gellens M, et al. 19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 1998; 9: 1427-32.
65. [65] Ross EA, Tian J, Abboud H, et al. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis. Am J Nephrol 2008; 28: 97-106.
66. [66] Lund RJ, Andress DL, Amdahl M, Williams LA, Heaney RP. Differential effects of paricalcitol and calcitriol on intestinal calcium absorption in hemodialysis patients. Am J Nephrol 2010; 31: 165-70.
67. [67] Cheng J, Zhang W, Zhang X, Li X, Chen J. Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis. Clin J Am Soc Nephrol 2012; 7: 391-400.
68. [68] Slatopolsky E, Cozzolino M, Lu Y, et al. Efficacy of 19-Nor-1,25-(OH)2D2 in the prevention and treatment of hyperparathyroid bone disease in experimental uremia. Kidney Int 2003; 63: 2020-7.
69. [69] Lau WL, Leaf EM, Hu MC, et al. Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet. Kidney Int 2012; 82(12): 1261-70.
70. [70] Lopez I, Mendoza FJ, Aguilera-Tejero E, et al. The effect of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic rats. Kidney Int 2008; 73: 300-7.
71. [71] Guerrero F, Montes de OA, Aguilera-Tejero E, Zafra R, Rodriguez M, Lopez I. The effect of vitamin D derivatives on vascular calcification associated with inflammation. Nephrol Dial Transplant 2012; 27: 2206-12.
72. [72] Bodyak N, Ayus JC, Achinger S, et al. Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci USA 2007; 104: 16810-5.
73. [73] Meems LM, Cannon MV, Mahmud H, et al. The vitamin D receptor activator paricalcitol prevents fibrosis and diastolic dysfunction in a murine model of pressure overload. J Steroid Biochem Mol Biol 2012; 132: 282-9.
74. [74] Thadhani R, Appelbaum E, Pritchett Y, et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 2012; 307: 674-84.
75. [75] Tamez H, Zoccali C, Packham D, et al. Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease. Am Heart J 2012; 164: 902-909.
76. [76] Freundlich M, Quiroz Y, Zhang Z, et al. Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. Kidney Int 2008; 74: 1394-402.
77. [77] Finch JL, Suarez EB, Husain K, et al. Effect of combining an ACE inhibitor and a VDR activator on glomerulosclerosis, proteinuria, and renal oxidative stress in uremic rats. Am J Physiol Renal Physiol 2012; 302: F141-149.
78. [78] Garcia IM, Altamirano L, Mazzei L, et al. Role of mitochondria in paricalcitol-mediated cytoprotection during obstructive nephropathy. Am J Physiol Renal Physiol 2012; 302: F1595-F1605.
79. [79] Sanchez-Nino MD, Bozic M, Cordoba-Lanus E, et al. Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy. Am J Physiol Renal Physiol 2012; 302: F647-F657.
80. [80] Bover J, DaSilva I, Furano M, et al. Clinical Uses of 1,25-dyhydroxy-19-nor-vitaminD2 (Paricalcitol). Curr Vasc Pharmacol 2013; 12(2): 313-23.
81. [81] de Zeeuw D, Agarwal R, Amdahl M, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010; 376: 1543-51.
82. [82] Weir MR. Short-term effects of vitamin D receptor activation on serum creatinine, creatinine generation, and glomerular filtration. Kidney Int 2011; 80(10): 1016-7.
83. [83] Dusso A. Update on the biologic role of the vitamin D endocrine system. Curr Vasc Pharamacol 2013; 12(2): 272-77.
84. [84] Tentori F, Albert JM, Young EW, et al. The survival advantage for haemodialysis patients taking vitamin D is questioned: findings from the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant 2009; 24: 963-72.
85. [85] Teng M, Wolf M, Ofsthun MN, et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16: 1115-25.
86. [86] Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349(5): 446-56.
87. [87] Cozzolino M, Brancaccio D, Cannella G, et al. VDRA therapy is associated with improved survival in dialysis patients with serum intact PTH <=150 pg/mL: results of the Italian FARO Survey. Nephrol Dial Transplant 2012; 27: 3588-94.
88. [88] Murayama E, Miyamoto K, Kubodera N, Mori T, Matsunaga I. Synthetic studies of vitamin D3 analogues. VIII. Synthesis of 22- oxavitamin D3 analogues. Chem Pharm Bull (Tokyo) 1986; 34(10): 4410-3.
89. [89] Mizobuchi M, Ogata H. Clinical uses of 22-Oxacalcitriol. Curr Vasc Pharmacol 2013; 12(2): 324-28.
90. [90] Shiizaki K, Negi S, Hatamura I, et al. Biochemical and Cellular Effects of Direct Maxacalcitol Injection into Parathyroid Gland in Uremic Rats. J Am Soc Nephrol 2005; 16: 97-108.
91. [91] Monier-Faugere MC, Geng Z, Friedler R. et al. 22-Oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure. Kidney International 1999; 55: 821-832.
92. [92] Okuno S, Ishimura E, Kitatani K, et al. Relationship between para- thyroid gland size and responsiveness to maxacalcitol therapy in patients with secondary hyperparathyroidism. Nephrol Dial Trans- plant 2003; 18: 2613-21.
93. [93] Ogata H, Koiwa F, Shishido K, et al. Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperpara- thyroidism. Ther Apher Dial 2007; 11: 202-9.
94. [94] Kazama JJ, Omori K, Takahashi N, et al, Maxacalcitol therapy decreases circulating osteoprotegerin levels in dialysis patients with secondary hyperparathyroidism. Clin Nephrol 2005; 64(1): 64-68. [95] Pasquali M, Tartaglione L, Rotondi S, Leonangeli C and Mazzaferro S. Further Vitamin D analogs. Curr Vasc Pharmacol 2013; 12(2): 329-38.
95. [96] Ito H, Ogata H, Yamamoto M, et al. Comparison of oral falecal-citriol and intravenous calcitriol in hemodialysis patients with sec- ondary hyperparathyroidism: a randomized, crossover trial. Clin Nephrol 2009; 71(6): 660-8.
96. [97] Hagino H, Takano T, Fukunaga M, Shiraki M, Nakamura T, Matsumoto T. Eldecalcitol reduces the risk of severe vertebral frac- tures and improves the health-related quality of life in patients with osteoporosis. J Bone Miner Metab 2012; 31(2): 183-9.
97. [98] Dalhoff K, Dancey J, Astrup L, et al. A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellu- lar carcinoma. Br J Cancer 2003; 89: 252-7.
98. [99] Adorini L, Penna G, Amuchastegui S, et al. Inhibition of prostate growth and inflammation by tha vitamin D receptor agonist BXL- 628 (elocalcitol). J Steroid Biochem Mol Biol 2007; 103: 689-93.
99. [100] Digesu GA, Verdi E, Cardozo L, Olivieri L, Khullar V, Colli E. Phase IIb, multicenter, double-blind, randomized, placebocontrolled, parallel-group study to determine effects of elocalcitol in women with overactive bladder and idiopathic detrusor overac- tivity. Urology 2012; 80(1): 48-54.